Head-to-head evidence
fluticasone propionate/salmeterol vs GW815SF
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline
fluticasone propionate/salmeterol
Developed by GlaxoSmithKline
NCT00920959 · Phase 3 · completed
The trial randomized 908 participants to combination therapy, fluticasone propionate, or placebo under double-blind conditions. Its primary endpoint was change in daily evening peak expiratory flow after 12 weeks, a pulmonary-function surrogate, and the registry does not report whether this endpoint was met.
GW815SF · Advair HFA
Marketed by GlaxoSmithKline
NCT00448435 · Phase 3 · completed
The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone propionate/salmeterol's landscape · GW815SF's landscape